• Arkom Cheirsilpa, Tanadej Sinthusake, Apinya Songsakkaesorn, Somchit Visawaprasit, Kemachit Chulaka, and Nunchaporn Changkuingdee.
• Division of Medical Oncology, National Cancer Institute, 268/1 Rama 6th Road, Rajthevi, Bangkok 10400, Thailand. silpa@health.moph.go.th
• Jpn. J. Clin. Oncol. 2005 Dec 1;35(12):695-9.

ObjectiveA clinical study of ramosetron was carried out to evaluate its efficacy in preventing both acute and delayed emesis in cisplatin-based chemotherapy by using a double-blind method with granisetron as the comparative drug.MethodsCisplatin at a dose of > or =70 mg/m(2) was administered as a single intravenous (i.v.) infusion over 4 h. Patients were randomly assigned to receive either ramosetron (0.3 mg i.v. bolus 30 min before cisplatin on Day 1 and a 0.1 mg tablet in the morning for Days 2 to 5 after completion of chemotherapy; n = 36) or granisetron (3 mg i.v. infusion 30 min before cisplatin on Day 1 and a 1 mg tablet in the morning for Days 2 to 5 after completion of chemotherapy; n = 37). The observation period started with the initiation of chemotherapy (0 h) and continued for 24 h after completion of the chemotherapy for acute emesis, and on Days 2 to 5 for delayed nausea and vomiting.ResultsA total of 73 patients were eligible for evaluation, with 36 patients in the ramosetron group and 37 in the granisetron group. The efficacy of both drugs was analyzed in terms of the degree of achievement in each day of treatment. Ramosetron was as effective as granisetron in preventing nausea and vomiting (both acute and delayed emesis). The two drugs had a similar safety profile and adverse events were generally mild and transient.ConclusionsRamosetron is effective and safe for the control of acute and delayed emesis induced by cisplatin.

34 keywords...

hide…